Cited by 237MRI in cancer diagnosisBreast Lesions and CarcinomasBreast Cancer Treatment Studies

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review

Open access

Lobbes, M. B. I., Prevos, R., Smidt, M., Tjan-Heijnen, V. C. G., van Goethem, M., Schipper, R., Beets-Tan, R. G., Wildberger, J. E.·2013·Insights into Imaging

DOI 10.1007/s13244-013-0219-yPMC PMC3609956

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVES: This systematic review aimed to assess the role of magnetic resonance imaging (MRI) in evaluating residual disease extent and the ability to detect pathologic complete response (pCR) after neoadjuvant chemotherapy for invasive breast cancer. METHODS: PubMed, the Cochrane Library, MEDLINE, and Embase databases were searched for relevant studies published until 1 July 2012. After primary selection, two reviewers independently assessed the content of each eligible study using a standardised extraction form and pre-defined inclusion and exclusion criteria. RESULTS: A total of 35 eligible studies were selected. Correlation coefficients of residual tumour size assessed by MRI and pathology were good, with a median value of 0.698. Reported sensitivity, specificity, positive predictive value and negative predictive value for predicting pCR with MRI ranged from 25 to 100 %, 50-97 %, 47-73 % and 71-100 %, respectively. Both overestimation and underestimation were observed. MRI proved more accurate in determining residual disease than physical examination, mammography and ultrasound. Diagnostic accuracy of MRI after neoadjuvant chemotherapy could be influenced by treatment regimen and breast cancer subtype. CONCLUSIONS: Breast MRI accuracy for assessing residual disease after neoadjuvant chemotherapy is good and surpasses other diagnostic means. However, both overestimation and underestimation of residual disease extent could be observed. MAIN MESSAGES: • Breast MRI accuracy for assessing residual disease is good and surpasses other diagnostic means. • Correlation coefficients of residual tumour size assessed by MRI and pathology were considered good. • However, both overestimation and underestimation of residual disease were observed. • Diagnostic accuracy of MRI seems to be affected by treatment regimen and breast cancer subtype.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s13244-013-0219-y

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Detailed overview of study selectionCC BY-NC · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Diagnostic Accuracy of Mammography, Clinical Examination, US, and MR Imaging in Preoperative Assessment of Breast Cancer
Berg, W. A., Gutierrez, L., NessAiver, M. S., Carter, W. B., Bhargavan, M., Lewis, R. S., & Ioffe, O. B. (2004) · Radiology · doi:10.1148/radiol.2333031484 · Cited by 1,441
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,214
Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening Mammography
Carney, P. A., Miglioretti, D. L., Yankaskas, B. C., Kerlikowske, K. M., Rosenberg, R., Rutter, C. M., Geller, B. M., Abraham, L., Taplin, S. H., Dignan, M., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00008 · Cited by 1,144
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL
Hylton, N. M., Blume, J. D., Bernreuter, W. K., Pisano, E. D., Rosen, M. A., Morris, E. A., Weatherall, P. T., Lehman, C. D., Newstead, G. M., Polin, S. M., et al. (2012) · Radiology · doi:10.1148/radiol.12110748 · Cited by 499
Prospective Comparison of Mammography, Sonography, and MRI in Patients Undergoing Neoadjuvant Chemotherapy for Palpable Breast Cancer
Yeh, E. D., Slanetz, P. J., Kopans, D. B., Rafferty, E. A., Georgian-Smith, D., Moy, L. P., Halpern, E. F., Moore, R. H., Kuter, I., & Taghian, A. G. (2005) · American Journal of Roentgenology · doi:10.2214/ajr.184.3.01840868 · Cited by 400
Accuracy of MR Imaging for Revealing Residual Breast Cancer in Patients Who Have Undergone Neoadjuvant Chemotherapy
Partridge, S. C., Gibbs, J., Lü, Y., Esserman, L. J., Sudilovsky, D., & Hylton, N. M. (2002) · American Journal of Roentgenology · doi:10.2214/ajr.179.5.1791193 · Cited by 337
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
Loo, C. E., Straver, M. E., Rodenhuis, S., Muller, S. H., Wesseling, J., Peeters, M.-J. T. F. D. V., & Gilhuijs, K. G. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1258 · Cited by 303
Diffusion-weighted MR Imaging: Pretreatment Prediction of Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
Park, S. H., Moon, W. K., Cho, N., Song, I. C., Chang, J. M., Park, I.-A., Han, W., & Noh, D. (2010) · Radiology · doi:10.1148/radiol.10092021 · Cited by 280

Show all 56 references

Sorted by citations

Items 201–237 of 237

Breast Cancer Imaging Pre- and Post-Neoadjuvant Systemic Therapy
Chung, S. H., & Raza, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-88020-0_9
Intervencionismo ecográfico en imagen mamaria
Goldaracena, J. M. O. (2022) · Radiología · doi:10.1016/j.rx.2021.11.003
Ultrasound-guided interventional procedures in breast imaging
Goldaracena, J. M. O. (2022) · Radiología (English Edition) · doi:10.1016/j.rxeng.2021.09.006
Predicting the response to Neoadjuvant Chemotherapy. Can the addition of tomosynthesis improve the accuracy of CESM? A comparison with breast MRIPreprint
Savaridas, S., Vinnicombe, S., Warwick, V., & Evans, A. J. (2022) · medRxiv · doi:10.1101/2022.08.26.22279254
Disease and Treatment Monitoring
Li, W., Newitt, D. C., Partridge, S. C., & Hylton, N. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-79702-3.00005-8
Neoadjuvant therapy response assessment with breast MRI
Arjmandi, F. K., & Doğan, B. E. (2022) · Advances in magnetic resonance technology and applications · doi:10.1016/b978-0-12-822729-9.00009-6
CEM and MR Radiomics-based Biomarkers to Predict Immunohistochemistry Breast Cancer Subtypes: A comparative studyPreprint
Iquebal, A. S., Zhou, S., Pfeiffer, N., Ranjbar, S., Banerjee, I., Swanson, K. R., Batalini, F., Anderson, K. S., Murtaza, M., Pockaj, B. A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2232518/v1
Diagnostic Value of Contrast-Enhanced Digital Mammography Versus Contrast-Enhanced MRI for Detecting Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer
Kim, E. Y., Yun, J.-S., Park, Y. L., Park, C. H., Kwon, M.-R., Moon, J. H., Youn, I., Choi, Y. J., & Kook, S. H. (2022) · Journal of Breast Disease · doi:10.14449/jbd.2022.10.2.69
Correlation between late gadolinium enhancement sequences in MRI and pathologic response after neoadjuvant chemotherapy in breast cancer
Cortés, G. H., de Vega, V. M., Cabero, S. F., Alonso, M. R., Cortijo, L. G., García, R. M., & Abbad, R. S. D. L. C. (2023) · Revista de Senología y Patología Mamaria · doi:10.1016/j.senol.2022.100438
Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, Multicenter Cohort StudyPreprint
Bae, S. J., Chun, J. W., Lee, S. B., Ryu, J. M., Nam, S. J., Jeong, J., Park, H. S., & Ahn, S. G. (2023) · Research Square · doi:10.21203/rs.3.rs-3036122/v1
The Effectiveness of Radiological Methods in Predicting Pathological Complete Response After Neoadjuvant Therapy in Locally Advanced Breast Cancer Patients
ERKAN, S., Yabanoğlu, H., GÜNDOĞDU, R., Avcı, T., & Çakmak, E. (2023) · Cukurova Anestezi ve Cerrahi Bilimler Dergisi · doi:10.36516/jocass.1294672
The Radiologist at the Center of Breast Conservation in the Management of Breast Cancer: A Case-Based Narrative Review of the Literature
(2023) · International Journal on Oncology and Radiotherapy · doi:10.51626/ijor.2023.04.00025
Contrast-Enhanced Spectral Mammography Versus Magnetic Resonance Imaging: Intra- and Inter-Observer Agreements in Tumour Size Assessment
Ko, T., Lai, A., Leung, B., Law, M., Wong, A., Chin, K., & Wong, W. (2024) · Hong Kong Journal of Radiology · doi:10.12809/hkjr2217606
THE METAL CLIPS AS BREAST CANCER MARKERS IN ASSESSMENT OF RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY
Gambarova, G. H., Asgarova, H. E., Aghamaliyeva, A. J., PANAKHOVA, M. S., AGABEYLY, L. Z., & Qorçiyeva, G. S. (2024) · World of Medicine and Biology · doi:10.26724/2079-8334-2024-2-88-28-32
Comparative Evaluation of USG-Guided Single Tissue Marker Versus Multiple Tissue Marker Placements in Breast Malignancy Patients Undergoing Neoadjuvant Chemotherapy for Tumor Localization
Yashaswinii, P., Christina, E. P., Ramaswami, S., Sl, H., & Natarajan, P. (2024) · Cureus · doi:10.7759/cureus.65355
MRI Breast Findings
Narasimhamurthy, M., O’Brien, S. R., Andrejeva, L., & Nayak, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65711-5_9
Efficacy of Mammographic Artificial Intelligence-Based Computer-Aided Detection in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy
Park, G. E., Kang, B. J., Kim, S. H., & Mun, H. S. (2024) · Life · doi:10.3390/life14111449
Dual-layer detector spectral computed tomography quantitative parameters for predicting pathological complete remission after neoadjuvant treatment of breast cancer
Guo, S., Wang, D., Zhao, Q., Bi, Z., Li, W., & Zhu, J. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-24-511
Optimization of radiotherapy in low-risk breast cancer patients
Civil, Y. A. (2025) · doi:10.5463/thesis.1151
Large Kernel MedNeXt for Breast Tumor Segmentation and Self-normalizing Network for pCR Classification in Magnetic Resonance Images
Musah, T. (2025) · Lecture notes in computer science · doi:10.1007/978-3-032-05559-0_8
The probability of axillary pathologic complete response in patients with breast radiologic complete response on breast MRI in triple-negative breast cancer treated with neoadjuvant chemotherapy
Claassens, E. L., van Amstel, F. J. G., de Boer, M., Lalji, U. C., Simons, J. M., Kooreman, L. F. S., Smidt, M. L., & van Nijnatten, T. J. A. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.111205
Self-citation
Emerging technologies for monitoring breast cancer response to neoadjuvant chemotherapy: a systematic scoping review
Wright, G. C., Glover, L., & Hubbard, T. J. E. (2025) · The Breast · doi:10.1016/j.breast.2025.104663
Contrast-Enhanced Mammography: A Comprehensive Overview of Current Status and Future Directions
Renganathan, R., Palanisamy, S., Kini, D. V., Subramaniam, P., Krishnappa, L., & Chang, J. M. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2025.0053
Additional file 2 of Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
Graeser, M., Schrading, S., Gluz, O., Strobel, K., Herzog, C., Umutlu, L., Frydrychowicz, A., Rjosk-Dendorfer, D., Würstlein, R., Culemann, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14247656
Additional file 3 of Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
Graeser, M., Schrading, S., Gluz, O., Strobel, K., Herzog, C., Umutlu, L., Frydrychowicz, A., Rjosk-Dendorfer, D., Würstlein, R., Culemann, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14247659
Additional file 1 of Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
Graeser, M., Schrading, S., Gluz, O., Strobel, K., Herzog, C., Umutlu, L., Frydrychowicz, A., Rjosk-Dendorfer, D., Würstlein, R., Culemann, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14247653
Additional file 1 of Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study
Bae, S. J., Chun, J. W., Lee, S. B., Ryu, J. M., Nam, S. J., Jeong, J., Park, H. S., & Ahn, S. G. (2024) · Figshare · doi:10.6084/m9.figshare.26708189
Additional file 4 of Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
Graeser, M., Schrading, S., Gluz, O., Strobel, K., Herzog, C., Umutlu, L., Frydrychowicz, A., Rjosk-Dendorfer, D., Würstlein, R., Culemann, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14247662
Primary tumour response on breast MRI as a predictor of axillary pathologic response in breast cancer patients treated with neoadjuvant chemotherapy
van Amstel, F. J. G., van Mierlo, R. G. M., Nelemans, P. J., Engelen, S. M. E., Houwers, J. B., Kooreman, L. F. S., Tjan‐Heijnen, V. C. G., Siesling, S., Smidt, M. L., & van Nijnatten, T. J. A. (2025) · European Radiology · doi:10.1007/s00330-025-12249-x
Self-citation
MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients
Damião, S. Q., da Cunha, E. F. R., Tavares, M. C., Sanches, S. M., Osorio, C. A. B. D. T., Brot, M. D., Makdissi, F. B. A., & Bitencourt, A. G. V. (2026) · British Journal of Radiology · doi:10.1093/bjr/tqag023
Subtle ground enhancement a new definition for breast magnetic resonance imaging (MRI) after neoadjuvant chemotherapy: is it a marker for microscopic residual disease?
Yılmaz, E., Mısır, M. E., Şeker, M. E., Güldoğan, N., Turk, E. B., Gorucu, H., & Arıbal, E. (2026) · Clinical Radiology · doi:10.1016/j.crad.2026.107349
Contributions of radiomics in ¹⁸F-FDG PET/CT and in MRI in breast cancer
Boughdad, S. (2018) · doi:10.70675/1a8762b2za62dz4c26z8154zd4a55ff7a2d7
Multimodal radiomics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer: integration of amide proton transfer weighted imaging in radiomics
Xu, M., Wang, A., Shan, D., Chen, X., Zhang, R., Xu, C., Yuan, J., Li, J., An, G., Shen, Z., et al. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02311-5
Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer
Bellini, C., Bicchierai, G., Maiello, C., Amato, F., Benedetto, D. D., Naro, F. D., Vidali, S., Tonelli, P., Vanzi, E., Boeri, C., et al. (2026) · European Radiology · doi:10.1007/s00330-026-12633-1
Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment
di Micco, R., Saraçoğlu, S., Pfob, A., Canevari, C., Gallivanone, F., Antunovic, L., Gelardi, F., Scifo, P., Neri, I., Losio, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1845216
A multimodal cross-temporal fusion system for complementary evaluation of neoadjuvant chemotherapy in breast cancer
Sun, X., Wang, D., Zhou, Q., Liu, W., Gao, X., Shen, X., Yang, X., Ma, T., Ma, T., Liu, C., et al. (2026) · European Journal of Radiology · doi:10.1016/j.ejrad.2026.113214
The REMINAC Study: rethinking surgical implications for REsidual MIcrocalcifications after NeoAdjuvant chemotherapy
D’Archi, S., Carnassale, B., Scardina, L., Accetta, C., Lauretis, F. D., Guglielmo, E. D., Franco, A., Gambaro, E., Magno, S., Moschella, F., et al. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.112159

Authors: Lobbes, M. B. I., Prevos, R., Smidt, M., Tjan-Heijnen, V. C. G., van Goethem, M., Schipper, R., Beets-Tan, R. G., & Wildberger, J. E.
Affiliations: Maastricht University Medical Centre (NL)
Corresponding author: Lobbes, M. B. I.
ORCID: Lobbes, M. B. I.
Smidt, M.
Schipper, R.
Wildberger, J. E.
Venue: Insights into Imaging
Publisher: Springer Science and Business Media LLC
Published: 2013-01-29
Volume: 4
Issue: 2
Pages: 163-175
ISSN: 1869-4101 (ISSN-L)
DOI: 10.1007/s13244-013-0219-y
PMC: PMC3609956
OpenAlex: W2057016707
Cited by: 237
References: 56
Citations by year: 2026: 10 · 2025: 15 · 2024: 27 · 2023: 21 · 2022: 22 · 2021: 25 · 2020: 15 · 2019: 23 · 2018: 16 · 2017: 24 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4
FWCI: 1.84
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by-nc/2.0 (unspecified)
Locations: Insights into Imaging (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
Research Publications (Maastricht University) (publishedVersion, cc-by)
Research Publications (Maastricht University) (submittedVersion, cc-by)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: breast MRI, residual disease, pathological complete response, neoadjuvant chemotherapy, invasive breast cancer, diagnostic accuracy, breast cancer subtypes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks